Securities code: 000756 securities abbreviation: Shandong Xinhua Pharmaceutical Company Limited(000756) Announcement No.: 2022-07 Shandong Xinhua Pharmaceutical Company Limited(000756)
Announcement on receiving the notice of China Securities Regulatory Commission on resumption of examination of administrative license application
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Shandong Xinhua Pharmaceutical Company Limited(000756) (hereinafter referred to as the “company”) submitted the application documents for non-public offering of shares to the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) on July 15, 2021, and received the acceptance form for administrative license application of the CSRC (acceptance No.: 211868) issued by the CSRC on July 19, 2021, On July 30, 2021, we received the notice on the first feedback on the examination of administrative licensing projects issued by the CSRC (No. 211868).
ShineWing Certified Public Accountants (special general partnership) hired by the company for this non-public offering of shares was filed for investigation by the CSRC, and the company received the notice on suspension of examination of administrative license application of the CSRC (No. 211868) issued by the CSRC, For details, please refer to the company’s announcement on securities times and cninfo (www.cn. Info. Com. CN.) on January 27, 2022 The announcement of Shandong Xinhua Pharmaceutical Company Limited(000756) on receiving the notice of China Securities Regulatory Commission on suspension of examination of administrative license application (Announcement No.: 2022-06) disclosed. After meeting the conditions for resumption of examination, the company shall submit an application to the CSRC to resume the examination of the application documents for this non-public offering of a shares.
On February 22, 2022, the company received the notice of the China Securities Regulatory Commission on the resumption of examination of administrative license application (No. 211868) issued by the China Securities Regulatory Commission. The China Securities Regulatory Commission decided to resume the examination of the application for administrative license of the company’s non-public offering in accordance with the relevant provisions of Article 23 of the provisions on the implementation procedures of administrative license of the China Securities Regulatory Commission.
The company’s non-public offering of shares still needs to be approved by the CSRC. Whether it can be approved and the approval time are still uncertain. The company will fulfill the obligation of information disclosure in time according to the review progress of the matter by the CSRC. Please pay attention to the investment risks.
It is hereby announced.
Shandong Xinhua Pharmaceutical Company Limited(000756) board of directors February 22, 2022
